Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis
Research output: Contribution to journal › Letter › Research › peer-review
Tocilizumab (TCZ), a monoclonal antibody targeting the human interleukin-6-receptor (IL-6R), is indicated for the treatment of rheumatoid arthritis (RA). We examined whether three IL6R single-nucleotide polymorphisms rs12083537, rs2228145 (formerly rs8192284), and rs4329505 with previously reported functional effects were associated with clinical response to TCZ in a retrospective study cohort consisting of 79 RA patients. Three months after initiation of TCZ therapy, changes in swollen joint count (SJC) and, subordinately, tender joint count (TJC), serum-CRP, DAS28-CRP, and EULAR-response were tested for association with the IL6R-haplotype or genotype. The major allele (A) of rs12083537 and the minor allele (C) of rs4329505 were associated with a poor SJC response (P=0.02 and 0.02, respectively). Moreover, the AAC-haplotype (for rs12083537, rs2228145, and rs4329505, respectively) was associated with a poor SJC response (P=0.00004) and, with borderline significance, EULAR-response (P=0.05). These data suggest that genetic variation in IL6R may aid in predicting TCZ therapy outcome in RA patients.
Original language | English |
---|---|
Journal | Pharmacogenetics and Genomics |
Volume | 24 |
Issue number | 8 |
Pages (from-to) | 401-405 |
Number of pages | 5 |
ISSN | 1744-6872 |
DOIs | |
Publication status | Published - Aug 2014 |
- Adult, Aged, Aged, 80 and over, Alleles, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Rheumatoid, Female, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Receptors, Interleukin-6, Retrospective Studies, Young Adult
Research areas
ID: 138143874